US 12,297,445 B2
Recombinant vector containing immunogenic protein of African swine fever virus, recombinant bacteria and use thereof
Wei Dong, Changsha (CN); Xiaohong Xie, Changsha (CN); Lixin Wen, Changsha (CN); Chaoliang Wu, Changsha (CN); Xin Li, Changsha (CN); Yuanyuan Zhu, Changsha (CN); Yongyong Zhang, Changsha (CN); and Jiahao Huang, Changsha (CN)
Assigned to CHANGSHA LVYE BIOTECHNOLOGY CO. LTD, Changsha (CN)
Appl. No. 17/299,375
Filed by CHANGSHA LVYE BIOTECHNOLOGY CO. LTD, Changsha (CN)
PCT Filed Aug. 18, 2020, PCT No. PCT/CN2020/109703
§ 371(c)(1), (2) Date Jun. 3, 2021,
PCT Pub. No. WO2021/217959, PCT Pub. Date Apr. 11, 2021.
Claims priority of application No. 202010339345.5 (CN), filed on Apr. 26, 2020.
Prior Publication US 2022/0315947 A1, Oct. 6, 2022
Int. Cl. C12N 15/86 (2006.01); A61K 35/00 (2006.01); A61K 35/747 (2015.01); A61K 39/12 (2006.01); A61P 31/20 (2006.01); C12N 1/20 (2006.01)
CPC C12N 15/86 (2013.01) [A61K 35/747 (2013.01); A61K 39/12 (2013.01); A61P 31/20 (2018.01); C12N 1/20 (2013.01); A61K 2035/115 (2013.01); C12N 2710/12034 (2013.01); C12N 2710/12043 (2013.01); C12N 2710/12052 (2013.01); C12N 2710/12071 (2013.01)] 4 Claims
 
1. An oral live bacteria preparation for preventing African swine fever infection, wherein the active ingredients of the oral live bacteria preparation comprise recombinant Lactobacillus expressing p72 protein of African swine fever virus and recombinant Lactobacillus expressing p54 protein of African swine fever virus;
wherein the recombinant Lactobacillus expressing p72 protein of African swine fever virus comprises a first recombinant vector containing a Lactobacillus expression vector pVE5523 with a nucleotide sequence encoding the p72 protein of African swine fever virus cloned between EcoRV and SaI restriction sites of the first recombinant vector, and
the recombinant Lactobacillus expressing p54 protein of African swine fever virus comprises a second recombinant vector containing a Lactobacillus expression vector pVE5523 with a nucleotide sequence encoding the p54 protein of African swine fever virus cloned between EcoRV and SaII restriction sites of the second recombinant vector; and
wherein upon administration of the preparation to a subject, the Lactobacillus secrete p54 and p72 antigen proteins capable of forming a biofilm on a mucus membrane of the subject that blocks binding of African swine fever virus.